CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to BioTime, Inc.	$ 7,438	$ (19,865)
Net loss allocable to non-controlling interest	(10,091)	(4,736)
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation of Asterias (Note 4)	(49,048)	0
Unrealized loss on equity method investment in Asterias at fair value	13,483	0
Depreciation expense	748	512
Amortization of intangible assets	2,292	2,628
Amortization of deferred license fees	150	55
Amortization of prepaid rent in common stock	0	42
Stock-based compensation	5,593	3,700
Subsidiary shareholder expense for subsidiary warrants	3,125	0
Amortization of discount on related party convertible debt	245	119
Accrued interest on convertible debt	46	9
BioTime's share of losses in equity method investment in Ascendance	333	0
Deferred income tax benefit	0	(2,448)
Bad debt expense	354	0
Changes in operating assets and liabilities:
Accounts and grants receivable, net	(54)	69
Inventory	0	(30)
Prepaid expenses and other current assets	(396)	(301)
Accounts payable and accrued liabilities	(211)	(810)
Other long-term liabilities	(84)	0
Deferred grant income	1,496	1,930
Deferred rent liabilities	81	(61)
Deferred revenues	(59)	151
Net cash used in operating activities	(24,559)	(19,036)
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of Asterias cash and cash equivalents (Note 3)	(8,376)	0
Purchase of equipment and other assets	(1,384)	(305)
Payments on construction in progress	(278)	(2,518)
Security deposit paid, net	22	(3)
Net cash used in investing activities	(10,016)	(2,826)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sales of BioTime common stock in public offering	17,500	0
Discounts and fees paid for sale of BioTime common stock in public offering	(1,105)	0
Proceeds from exercises of stock options	2,015	621
Proceeds from exercise of warrants	0	19
Proceeds from sale of treasury stock and subsidiary warrants	0	11,700
Reimbursement from landlord on construction in progress	411	560
Proceeds from issuance of related party convertible debt	1,019	188
Repayment of capital lease obligation	(74)	(28)
Net proceeds from sale of common shares of subsidiary	171	11,586
Fees paid on sale of common shares of subsidiary	(206)	(597)
Proceeds from exercise of subsidiary stock options	0	23
Net cash provided by financing activities	19,731	24,072
Effect of exchange rate changes on cash and cash equivalents	317	(232)
NET CHANGE IN CASH AND CASH EQUIVALENTS:	(14,527)	1,978
CASH AND CASH EQUIVALENTS:
At beginning of the period	42,229	29,487
At end of the period	$ 27,702	$ 31,465